Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 651–660 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 651
- Medicine slug
- fosaprepitant-dimeglumine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 27
- Source count
- 27
- Agreement rate
- 1
- Recorded readings
9 to 13 hours
- Numeric value
- 9
- Unit
- hours
- Source records
- 27
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 27 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d624667d-ee3b-3501-53fe-da453352042d (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-liferanged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffee61d1-c1c6-4224-871c-ab7ff6cd01e5 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bb41bcb-c775-4447-9bd0-d4c55ad110ea (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df341f63-0fef-4411-a89b-6df6b9e792be (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf207918-100d-4917-88b0-3433c0e72249 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d30d839-bb88-46ce-a9ed-66fe32a12a7a (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46edae30-d50c-4112-9941-954b13ed5eda (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21b08b87-70e3-4233-9531-dd6d84eab5d0 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cc7d482-5d45-4621-9ffc-cd3f7c54614d (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b6d5ea3-2f7a-4501-9a4a-6fa1a7c2d50a (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ed3e0a9-a0a8-4555-9f73-2043e79e3398 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a7d2f44-b578-4d99-a4ff-f267626064d0 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f942e4c-e26a-4155-9e14-344b2970b189 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18a60093-cec8-1b8c-e063-6394a90a8902 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7afe33d8-5416-465a-b98b-f4eedc327a94 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7343abe-b2b0-4e5a-907b-532a8e16dfcb (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dbd4c29-d894-4839-9b22-a2f65c8c8ad1 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d66803a-6811-4c29-9c57-e16acfa87f21 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19919480-960b-4741-9611-c133d68512f5 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7375ab3f-a6fc-4601-9415-07b4f681cdef (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:679c195a-cf59-4ca5-aa05-fa35d08ddb5c (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a41b7c3a-1376-43a7-b5b9-6ba2eba1e169 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:557a48d5-0e1f-f3d5-d3bc-db422d19c399 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f34c931c-78b9-90c1-3fa5-bb34a227f2ad (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-liferanged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad89825f-aa31-469f-9685-159a4524dfdc (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7dbdf8f5-6936-4143-b52d-96774b799a7d (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e6b36b2-3c8b-4ac4-827e-d6f00d999032 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The apparent terminal half-life ranged from approximately 9 to 13 hours.
Projected row 652
- Medicine slug
- fosaprepitant-dimeglumine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 27
- Source count
- 27
- Agreement rate
- 1
- Recorded readings
70 L
- Numeric value
- 70
- Unit
- L
- Source records
- 27
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 27 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d624667d-ee3b-3501-53fe-da453352042d (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state(Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffee61d1-c1c6-4224-871c-ab7ff6cd01e5 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bb41bcb-c775-4447-9bd0-d4c55ad110ea (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df341f63-0fef-4411-a89b-6df6b9e792be (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf207918-100d-4917-88b0-3433c0e72249 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d30d839-bb88-46ce-a9ed-66fe32a12a7a (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46edae30-d50c-4112-9941-954b13ed5eda (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21b08b87-70e3-4233-9531-dd6d84eab5d0 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cc7d482-5d45-4621-9ffc-cd3f7c54614d (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b6d5ea3-2f7a-4501-9a4a-6fa1a7c2d50a (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ed3e0a9-a0a8-4555-9f73-2043e79e3398 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a7d2f44-b578-4d99-a4ff-f267626064d0 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f942e4c-e26a-4155-9e14-344b2970b189 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18a60093-cec8-1b8c-e063-6394a90a8902 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7afe33d8-5416-465a-b98b-f4eedc327a94 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7343abe-b2b0-4e5a-907b-532a8e16dfcb (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dbd4c29-d894-4839-9b22-a2f65c8c8ad1 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d66803a-6811-4c29-9c57-e16acfa87f21 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19919480-960b-4741-9611-c133d68512f5 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7375ab3f-a6fc-4601-9415-07b4f681cdef (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:679c195a-cf59-4ca5-aa05-fa35d08ddb5c (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a41b7c3a-1376-43a7-b5b9-6ba2eba1e169 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vdss) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:557a48d5-0e1f-f3d5-d3bc-db422d19c399 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vdss) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f34c931c-78b9-90c1-3fa5-bb34a227f2ad (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state(Vd ss ) was approximately 70 L in humans.Aprepitant crossesthe blood brainbarrier in humans[see Clinical Pharmacology ( 12.1 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad89825f-aa31-469f-9685-159a4524dfdc (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7dbdf8f5-6936-4143-b52d-96774b799a7d (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e6b36b2-3c8b-4ac4-827e-d6f00d999032 (opens source in a new tab)
Fosaprepitant Dimeglumine label
Version not recorded · Effective date not recorded
The mean apparent volume of distribution at steady state (Vd ss ) was approximately 70 L in humans.
Projected row 653
- Medicine slug
- foscarnet
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
87.5 ± 41.8 hours
- Numeric value
- 87.5
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b612e6f1-584f-4188-b96e-1a9adfcfe75c (opens source in a new tab)
Foscarnet label
Version not recorded · Effective date not recorded
The foscarnet terminal half-life determined by urinary excretion was 87.5 ± 41.8 hours, possibly due to release of foscarnet from bone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90e3da4e-3b1f-428b-99ca-e4bed1c80028 (opens source in a new tab)
Foscarnet label
Version not recorded · Effective date not recorded
The foscarnet terminal half-life determined by urinary excretion was 87.5 ± 41.8 hours, possibly due to release of foscarnet from bone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b03cbb8e-f555-4ed3-854e-dd962604f144 (opens source in a new tab)
Foscarnet label
Version not recorded · Effective date not recorded
The foscarnet terminal half-life determined by urinary excretion was 87.5 ± 41.8 hours, possibly due to release of foscarnet from bone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a7caffd-9d8a-4d45-ad48-70d511a89c29 (opens source in a new tab)
Foscarnet label
Version not recorded · Effective date not recorded
The foscarnet terminal half-life determined by urinary excretion was 87.5 ± 41.8 hours, possibly due to release of foscarnet from bone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4048736-389f-48d8-aadd-6bc76d604ddb (opens source in a new tab)
Foscarnet label
Version not recorded · Effective date not recorded
The foscarnet terminal half-life determined by urinary excretion was 87.5 ± 41.8 hours, possibly due to release of foscarnet from bone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ec3bb2a-fb40-4d4a-bc1b-feea80cc1a95 (opens source in a new tab)
Foscarnet label
Version not recorded · Effective date not recorded
The foscarnet terminal half-life determined by urinary excretion was 87.5 ± 41.8 hours, possibly due to release of foscarnet from bone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a09299d5-9c55-4cef-aed0-3a6a45532289 (opens source in a new tab)
Foscarnet label
Version not recorded · Effective date not recorded
The foscarnet terminal half-life determined by urinary excretion was 87.5 ± 41.8 hours, possibly due to release of foscarnet from bone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2b4ce68-5a81-4b14-8914-21bc38f01008 (opens source in a new tab)
Foscarnet label
Version not recorded · Effective date not recorded
The foscarnet terminal half-life determined by urinary excretion was 87.5 ± 41.8 hours, possibly due to release of foscarnet from bone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:335f7deb-a045-43cb-b319-d7b73bfda73c (opens source in a new tab)
Foscarnet label
Version not recorded · Effective date not recorded
The foscarnet terminal half-life determined by urinary excretion was 87.5 ± 41.8 hours, possibly due to release of foscarnet from bone.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f49c1bc-0828-4e5c-a3c0-81e997213b0e (opens source in a new tab)
Foscarnet label
Version not recorded · Effective date not recorded
The foscarnet terminal half-life determined by urinary excretion was 87.5 ± 41.8 hours, possibly due to release of foscarnet from bone.
Projected row 654
- Medicine slug
- fosfomycin
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 8
- Agreement rate
- 1
- Recorded readings
37%
- Numeric value
- 37
- Unit
- %
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d101b5d8-bffc-4ee6-b93b-4589fcb8750d (opens source in a new tab)
Fosfomycin label
Version not recorded · Effective date not recorded
Absolute oral bioavailability under fasting conditions is 37%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aacd04a4-f2d5-45a2-b9e7-0e92244a5880 (opens source in a new tab)
Fosfomycin label
Version not recorded · Effective date not recorded
Absolute oral bioavailability under fasting conditions is 37%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3fa61bd4-fc55-0987-e063-6394a90abce2 (opens source in a new tab)
Fosfomycin label
Version not recorded · Effective date not recorded
Absolute oral bioavailability under fasting conditions is 37%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8ec4771-3f8d-473a-a1d0-e42038f61a42 (opens source in a new tab)
Fosfomycin label
Version not recorded · Effective date not recorded
Absolute oral bioavailability under fasting conditions is 37%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48e352bc-52ea-4778-905a-60ef38a5c18a (opens source in a new tab)
Fosfomycin label
Version not recorded · Effective date not recorded
Absolute oral bioavailability under fasting conditions is 37%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f44b79d0-a789-46cb-ab70-7eb33a7debaf (opens source in a new tab)
Fosfomycin label
Version not recorded · Effective date not recorded
Absolute oral bioavailability under fasting conditions is 37%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b9167a9-80e9-44e1-a609-c3eb78960acf (opens source in a new tab)
Fosfomycin label
Version not recorded · Effective date not recorded
Absolute oral bioavailability under fasting conditions is 37%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f206750-8126-99a3-e063-6294a90ade4c (opens source in a new tab)
Fosfomycin label
Version not recorded · Effective date not recorded
Absolute oral bioavailability under fasting conditions is 37%.
Projected row 655
- Medicine slug
- fosinopril
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
11 to 13 hours
- Numeric value
- 11
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff1323cc-7ad8-488d-94a7-a11555db78a7 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of fosinoprilat in pediatric patients was 11 to 13 hours, also similar to that observed in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:880e5bf4-ced8-4765-a5c2-2361fd06ed9c (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of fosinoprilat in pediatric patients was 11 to 13 hours, also similar to that observed in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:736fe52f-69fb-48b2-b1c5-f06531878538 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of fosinoprilat in pediatric patients was 11 to 13 hours, also similar to that observed in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a66f606-5e6f-473d-8a1e-9ef316adb2e2 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of fosinoprilat in pediatric patients was 11 to 13 hours, also similar to that observed in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee78de8e-22f4-4c3b-a721-e9464d704eda (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of fosinoprilat in pediatric patients was 11 to 13 hours, also similar to that observed in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc38f1bb-f175-4a81-8ed9-c8701efdea35 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of fosinoprilat in pediatric patients was 11 to 13 hours, also similar to that observed in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6562a532-b502-4515-88df-591d71293b56 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of fosinoprilat in pediatric patients was 11 to 13 hours, also similar to that observed in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aee04f17-8ee9-42f5-861f-b6ba17220ca4 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of fosinoprilat in pediatric patients was 11 to 13 hours, also similar to that observed in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2ff3171-a17a-456a-9272-ca1682b01d19 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of fosinoprilat in pediatric patients was 11 to 13 hours, also similar to that observed in adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46e3e4e8-c611-4d4f-ad57-050b4c01fcd8 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
The terminal elimination half-life of fosinoprilat in pediatric patients was 11 to 13 hours, also similar to that observed in adults.
Projected row 656
- Medicine slug
- fosinopril
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff1323cc-7ad8-488d-94a7-a11555db78a7 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
Times to peak concentrations are independent of dose and are achieved in approximately 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:880e5bf4-ced8-4765-a5c2-2361fd06ed9c (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
Times to peak concentrations are independent of dose and are achieved in approximately 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:736fe52f-69fb-48b2-b1c5-f06531878538 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
Times to peak concentrations are independent of dose and are achieved in approximately 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a66f606-5e6f-473d-8a1e-9ef316adb2e2 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
Times to peak concentrations are independent of dose and are achieved in approximately 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee78de8e-22f4-4c3b-a721-e9464d704eda (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
Times to peak concentrations are independent of dose and are achieved in approximately 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc38f1bb-f175-4a81-8ed9-c8701efdea35 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
Times to peak concentrations are independent of dose and are achieved in approximately 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6562a532-b502-4515-88df-591d71293b56 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
Times to peak concentrations are independent of dose and are achieved in approximately 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aee04f17-8ee9-42f5-861f-b6ba17220ca4 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
Times to peak concentrations are independent of dose and are achieved in approximately 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2ff3171-a17a-456a-9272-ca1682b01d19 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
Times to peak concentrations are independent of dose and are achieved in approximately 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46e3e4e8-c611-4d4f-ad57-050b4c01fcd8 (opens source in a new tab)
Fosinopril label
Version not recorded · Effective date not recorded
Times to peak concentrations are independent of dose and are achieved in approximately 3 hours.
Projected row 657
- Medicine slug
- fosphenytoin
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 0.9
- Recorded readings
12.0 to 28.9 hr
- Numeric value
- 12
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4c36fad-0ba2-4cd4-9c5e-dcf843f38a5a (opens source in a new tab)
Fosphenytoin label
Version not recorded · Effective date not recorded
Elimination : Mean total phenytoin half-life values (12.0 to 28.9 hr) following CEREBYX administration at these doses are similar to those after equal doses of parenteral Dilantin and tend to be greater at higher plasma phenytoin concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb38bc6a-99c7-4cda-b3f0-37f629d060cf (opens source in a new tab)
Fosphenytoin label
Version not recorded · Effective date not recorded
Elimination: Mean total phenytoin half-life values (12.0 to 28.9 hr) following fosphenytoin sodium administration at these doses are similar to those after equal doses of parenteral Dilantin and tend to be greater at higher plasma phenytoin concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b60c9c82-e5c7-4e05-98c7-5bbba4af04b2 (opens source in a new tab)
Fosphenytoin label
Version not recorded · Effective date not recorded
Elimination : Mean total phenytoin half-life values (12.0 to 28.9 hr) following fosphenytoin sodium injection administration at these doses are similar to those after equal doses of parenteral phenytoin sodium and tend to be greater at higher plasma phenytoin concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de5a6711-4abb-4c3d-a18b-266b094ace11 (opens source in a new tab)
Fosphenytoin label
Version not recorded · Effective date not recorded
Elimination : Mean total phenytoin half-life values (12.0 to 28.9 hr) following CEREBYX administration at these doses are similar to those after equal doses of parenteral Dilantin and tend to be greater at higher plasma phenytoin concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:519a44e3-8a93-456c-b71c-894513810d45 (opens source in a new tab)
Fosphenytoin label
Version not recorded · Effective date not recorded
Elimination : Mean total phenytoin half-life values (12.0 to 28.9 hr) following fosphenytoin sodium injection administration at these doses are similar to those after equal doses of parenteral Dilantin and tend to be greater at higher plasma phenytoin concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0def32c-e693-43e5-9509-0cef9642441c (opens source in a new tab)
Fosphenytoin label
Version not recorded · Effective date not recorded
Elimination: Mean total phenytoin half-life values (12.0 to 28.9 hr) following fosphenytoin sodium administration at these doses are similar to those after equal doses of parenteral Dilantin and tend to be greater at higher plasma phenytoin concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49b08648-6a83-42c7-ae7b-80c29f2534fc (opens source in a new tab)
Fosphenytoin label
Version not recorded · Effective date not recorded
Elimination: Mean total phenytoin half-life values (12.0 to 28.9 hr) following fosphenytoin sodium administration at these doses are similar to those after equal doses of parenteral Dilantin and tend to be greater at higher plasma phenytoin concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c92df63b-5140-4213-8d43-8327ff6230b7 (opens source in a new tab)
Fosphenytoin label
Version not recorded · Effective date not recorded
Elimination: Mean total phenytoin half-life values (12.0 to 28.9 hr) following Fosphenytoin Sodium Injection administration at these doses are similar to those after equal doses of parenteral Dilantin and tend to be greater at higher plasma phenytoin concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1dab8ad-cbf6-4273-92fa-02629de2abde (opens source in a new tab)
Fosphenytoin label
Version not recorded · Effective date not recorded
Elimination: Mean total phenytoin half-life values (12.0 to 28.9 hr) following fosphenytoin sodium administration at these doses are similar to those after equal doses of parenteral Dilantin and tend to be greater at higher plasma phenytoin concentrations.
12 to 28.9 hr
- Numeric value
- 12
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87ff8a91-5b37-401c-b75c-dc6efd348761 (opens source in a new tab)
Fosphenytoin label
Version not recorded · Effective date not recorded
Mean total phenytoin half-life values (12 to 28.9 hr) following fosphenytoin injection administration at these doses are similar to those after equal doses of parenteral phenytoin sodium and tend to be greater at higher plasma phenytoin concentrations.
Projected row 658
- Medicine slug
- frovatriptan
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
26 hours
- Numeric value
- 26
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d303af88-e0c1-4fb2-ba8e-83b7e6d163cd (opens source in a new tab)
Frovatriptan label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of frovatriptan in both males and females is approximately 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92c91060-c06e-4a8a-b586-a3fb25c33433 (opens source in a new tab)
Frovatriptan label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of frovatriptan in both males and females is approximately 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94b996dc-ddc4-41ce-9a9f-3d91cb187473 (opens source in a new tab)
Frovatriptan label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of frovatriptan in both males and females is approximately 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03a58215-dba7-4f63-8b98-d74d054a574a (opens source in a new tab)
Frovatriptan label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life of frovatriptan in both males and females is approximately 26 hours.
Projected row 659
- Medicine slug
- fulvestrant
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 1
- Recorded readings
40 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:477098a1-cd37-48ad-b17f-aef610cb0f57 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57352662-d2fa-4dce-828f-4c51e46e0b4d (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a51aa693-b433-4b2d-a71b-9ba029b10ce3 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f05b699-c440-42c1-9557-46759a10ab17 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e20d8ca3-8837-4003-8b01-1ebec342062a (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99cf8b69-4c23-4886-80e9-b23e348b5bd7 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b02915fe-6c44-48c1-aaeb-997ddc59a595 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:994edf79-20a5-4e3a-bb35-c4fe3e65acba (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:306c283b-9abe-4985-856b-1957f1f3af8b (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46086fe7-190d-4963-97bc-1fe22d36e6d2 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f36f19ad-f044-4dba-80b6-d074ddffcd86 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67566681-19b5-89df-2030-25df5b0cf641 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f44cffcc-8f5e-4a4c-a36e-ab946ce86266 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fabe9bd8-ac23-4df1-a89a-223d5cd38914 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80b6dfe6-449d-4e2f-af90-bfbf9b04163b (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83d7a440-e904-4e36-afb5-cb02b1c919f7 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:840cd7c0-9f33-f74e-f136-de7fe899bfb4 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a03f714-b109-4256-80a6-78c82127d624 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ed06e0e-c17b-4c71-8d03-888bcde4a638 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5ae9e07-73b0-4063-a9e4-0ffc5614c2b8 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b471eb51-488e-5312-e053-2a95a90a8116 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc7b4eac-3b63-53d2-e053-2995a90ad5e7 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:015fafb6-23f7-4566-9c23-386eee7b035d (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:141f439e-078c-4a59-acff-ebf7685f55b8 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
After an intramuscular injection of 250 mg, the clearance (Mean ± SD) was 690 ± 226 mL/min with an apparent half-life about 40 days.
Projected row 660
- Medicine slug
- fulvestrant
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 0.92
- Recorded readings
3 to 5 L/kg
- Numeric value
- 3
- Unit
- L/kg
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:477098a1-cd37-48ad-b17f-aef610cb0f57 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
e given on Day 15 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state Month 3 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57352662-d2fa-4dce-828f-4c51e46e0b4d (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
Month 3 Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f05b699-c440-42c1-9557-46759a10ab17 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
ng.hr/mL) 500 mg + AD 1 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state 2 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e20d8ca3-8837-4003-8b01-1ebec342062a (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
Month 3 Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99cf8b69-4c23-4886-80e9-b23e348b5bd7 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
6.3 (25.9) 11400 (33.4) Multiple dose steady state 2 28 (27.9) 12.2 (21.7) 13100 (23.4) 1 Additional 500 mg dose given on Day 15 2 Month 3 Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b02915fe-6c44-48c1-aaeb-997ddc59a595 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
Month 3 Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:994edf79-20a5-4e3a-bb35-c4fe3e65acba (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
3 (25.9) 11400 (33.4) Multiple dose steady state 2 28.0 (27.9) 12.2 (21.7) 13100 (23.4) 1 Additional 500 mg dose given on Day 15 2 Month 3 Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:306c283b-9abe-4985-856b-1957f1f3af8b (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
e given on Day 15 Single dose 25.1 (35.3) 16.3 (25.9) 11,400 (33.4) Multiple dose steady state Month 3 28 (27.9) 12.2 (21.7) 13,100 (23.4) Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46086fe7-190d-4963-97bc-1fe22d36e6d2 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
Month 3 C max (ng/mL) C min (ng/mL) AUC (ng.hr/mL) 500 mg + AD 1 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state 2 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67566681-19b5-89df-2030-25df5b0cf641 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
ng.hr/mL) 500 mg + AD * Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state † 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f44cffcc-8f5e-4a4c-a36e-ab946ce86266 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
Month 3 C max (ng/mL) C min (ng/mL) AUC (ng.hr/mL) 500 mg + AD 1 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state 2 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fabe9bd8-ac23-4df1-a89a-223d5cd38914 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
Month 3 C max (ng/mL) C min (ng/mL) AUC (ng.hr/mL) 500 mg + AD 1 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state 2 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80b6dfe6-449d-4e2f-af90-bfbf9b04163b (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
ng.hr/mL) 500 mg + AD 1 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state 2 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83d7a440-e904-4e36-afb5-cb02b1c919f7 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
e given on Day 15 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state Month 3 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:840cd7c0-9f33-f74e-f136-de7fe899bfb4 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
ng.hr/mL) 500 mg + AD * Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state † 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a03f714-b109-4256-80a6-78c82127d624 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
dose given on Day 15 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state Month 3 28 (27.9) 12.2 (21.7) 13100 (23.4) Distribution The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ed06e0e-c17b-4c71-8d03-888bcde4a638 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
Month 3 C max (ng/mL) C min (ng/mL) AUC (ng.hr/mL) 500 mg + AD 1 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state 2 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
3 (25.9) 11400 (33.4) Multiple dose steady state 2 28.0 (27.9) 12.2 (21.7) 13100 (23.4) 1 Additional 500 mg dose given on Day 15 2 Month 3 Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5ae9e07-73b0-4063-a9e4-0ffc5614c2b8 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
ng.hr/mL) 500 mg + AD 1 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state 2 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b471eb51-488e-5312-e053-2a95a90a8116 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
e given on Day 15 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state Month 3 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution: The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc7b4eac-3b63-53d2-e053-2995a90ad5e7 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
Month 3 Distribution: The apparent volume of distribution at steady-state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:015fafb6-23f7-4566-9c23-386eee7b035d (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
(ng.hr/mL) 500 mg + AD 1 Single dose 25.1 (35.3) 16.3 (25.9) 11400 (33.4) Multiple dose steady state 2 28.0 (27.9) 12.2 (21.7) 13100 (23.4) Distribution The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:141f439e-078c-4a59-acff-ebf7685f55b8 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
16.3 (25.9) 11400 (33.4) Multiple dose steady state † 28 (27.9) 12.2 (21.7) 13100 (23.4) * Additional 500 mg dose given on Day 15 † Month 3 Distribution The apparent volume of distribution at steady state is approximately 3 to 5 L/kg.
3 L/kg
- Numeric value
- 3
- Unit
- L/kg
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a51aa693-b433-4b2d-a71b-9ba029b10ce3 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
Month 3 Distribution: The apparent volume of distribution at steady-state is approximately 3 L/kg to 5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f36f19ad-f044-4dba-80b6-d074ddffcd86 (opens source in a new tab)
Fulvestrant label
Version not recorded · Effective date not recorded
Month 3 Distribution: The apparent volume of distribution at steady-state is approximately 3 L/kg to 5 L/kg.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=650Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.